



**Australian Government**

**Department of Health and Aged Care**

Australian Industrial Chemicals Introduction Scheme

# **Chemicals that are unlikely to require further regulation to manage risks to human health**

**Evaluation statement**

**26 June 2023**



# Table of contents

## Contents

AICIS evaluation statement .....	3
Subject of the evaluation.....	3
Chemicals in this evaluation.....	3
Reason for the evaluation .....	3
Parameters of evaluation .....	3
Summary of evaluation .....	4
Summary of introduction, use and end use.....	4
Human health.....	4
Conclusions .....	5
Supporting information .....	6
References .....	10

# AICIS evaluation statement

## Subject of the evaluation

Chemicals that are unlikely to require further regulation to manage risks to human health.

## Chemicals in this evaluation

See supporting information for the list of chemicals included in the evaluation.

## Reason for the evaluation

Evaluation is needed to provide information on human health risks.

## Parameters of evaluation

This evaluation provides information on chemicals, listed on the Australian Inventory of Industrial Chemicals (the Inventory), identified during the Evaluation Selection Analysis (ESA) process as unlikely to require further regulation to manage risks to health. The ESA considers the intrinsic hazard of the chemical, the potential human exposure and existing risk management measures.

Based on the use category, the ESA process first sought to validate the absence of the following hazards:

- Site limited; neurotoxic, carcinogenic, mutagenic or a reproductive toxin.
- Commercial; as above, plus very high acute toxicity, high repeat dose toxicity, high corrosivity and respiratory sensitisation.
- Domestic; as above plus moderate acute toxicity, moderate repeat dose toxicity, skin sensitisation and moderate corrosivity.
- Cosmetic; any classifiable hazard, including harmful by acute exposure and irritating to skin and eyes.

Where these hazards were identified, we considered whether the hazards would be present under the likely conditions of use, which were determined based on available information. For example, where a chemical is irritating because of its extreme pH, and the formulated product will be at a more neutral pH, the irritant property is not relevant to the product. This evaluation statement provides key information used during the ESA process including the highest use category and additional information on any factors that have contributed to risk conclusions.

During the ESA, we may also identify chemicals that are only used in laboratories in very small quantities. No evaluation of hazards was undertaken for these chemicals.

# Summary of evaluation

## Summary of introduction, use and end use

See supporting information for the highest use category identified for each chemical. The categories used by AICIS, in order of increasing exposure, are:

- Non-industrial excluded uses (only); food, therapeutic, agricultural, and veterinary.
- Site limited; only used in large chemical operations.
- Commercial; used by small factories, scattered through the community, industrial cleaning, operations, and rare use by specialised hobbyist members of the public.
- Domestic; used in products generally available to the public, excluding cosmetics.
- Cosmetic; personal care products.

## Human health

### Summary of health risk

#### Public

Based on the available information, there are no identified risks to the public that require further regulation to manage the risk to human health. Although some of the chemicals with cosmetic and domestic uses may have potential health hazards, risks to the public are minimised by:

- the concentrations to which the public are exposed
- normal precautions being taken when using domestic products to avoid skin and eye contact
- the systemic bioavailability of chemicals.

See supporting information for additional information on any factors that have contributed to the risk conclusions. Any requirements under poisons legislation as adopted by the relevant state or territory should be met to minimise risk.

#### Workers

Based on the available information, there are no identified risks to workers that require further regulation to manage the risk to health.

Although chemicals in this evaluation may meet the criteria for classification according to the Globally Harmonized System of Classification and Labelling of Chemicals (GHS) based on the highest category of use identified (see **Supporting information**), controls to manage the risk to workers are expected to be in place.

All requirements under workplace health and safety as adopted by the relevant state or territory should be met to minimise risk.

## Conclusions

The conclusions of this evaluation are based on the information described in this statement.

Considering the proposed means of managing risks, the Executive Director is satisfied that the identified human health risks can be managed within existing risk management frameworks. This is provided that all requirements are met under environmental, workplace health and safety and poisons legislation as adopted by the relevant state or territory and the proposed means of managing the risks identified during this evaluation are implemented.

Note: Obligations to report additional information about hazards under *Section 100* of the *Industrial Chemicals Act 2019* apply.

## Supporting information

CAS No	Chemical Name	Highest Use Category (Human Health)	Additional information
62-33-9	Calciate(2-), [[N,N'-1,2-ethanediylbis[N-(carboxymethyl)glycinato]](4-)-N,N',O,O',ON,ON']-, disodium, (OC-6-21)-	Cosmetic	-
103-83-3	Benzenemethanamine, N,N-dimethyl-	Commercial	-
141-01-5	2-Butenedioic acid, (E)-, iron(2+) salt (1:1)	Cosmetic	-
7704-73-6	2-Butenedioic acid, (E)-, sodium salt	Cosmetic	-
7705-12-6	2-Butenedioic acid, (E)-, iron(2+) salt	Cosmetic	-
8013-07-8	Soybean oil, epoxidized	Cosmetic	-
8016-11-3	Linseed oil, epoxidized	Commercial	-
12389-75-2	Ferrate(2-), [N,N-bis[2-[bis(carboxymethyl)amino]ethyl]glycinato(5-)]-, sodium hydrogen, (PB-7-13-12564)-	Domestic	-
14025-15-1	Cuprate(2-), [[N,N'-1,2-ethanediylbis[N-(carboxymethyl)glycinato]](4-)-N,N',O,O',ON,ON']-, disodium, (OC-6-21)-	Cosmetic	-
14025-21-9	Zincate(2-), [[N,N'-1,2-ethanediylbis[N-(carboxymethyl)glycinato]](4-)-N,N',O,O',ON,ON']-, disodium, (OC-6-21)-	Domestic	-
14402-88-1	Magnesate(2-), [[N,N'-1,2-ethanediylbis[N-(carboxymethyl)glycinato]](4-)-N,N',O,O',ON,ON']-, disodium, (OC-6-21)-	Domestic	-
14729-89-6	Ferrate(2-), [[N,N'-1,2-ethanediylbis[N-(carboxymethyl)glycinato]](4-)-N,N',O,O',ON,ON']-, disodium, (OC-6-21)-	Commercial	-
15375-84-5	Manganate(2-), [[N,N'-1,2-ethanediylbis[N-(carboxymethyl)glycinato]](4-)-N,N',O,O',ON,ON']-, disodium, (OC-6-21)-	Domestic	-

CAS No	Chemical Name	Highest Use Category (Human Health)	Additional information
15708-41-5	Ferrate(1-), [[N,N'-1,2-ethanediylbis[N-(carboxymethyl)glycinato]](4-)-N,N',O,O',ON,ON']-, sodium, (OC-6-21)-	Domestic	-
16485-47-5	Ferrate(1-), [N-[2-[bis(carboxymethyl)amino]ethyl]-N-(2-hydroxyethyl)glycinato(3-)]-, sodium	Domestic	-
16809-23-7	Glycine, N,N'-1,2-ethanediylbis[N-(carboxymethyl)-, zinc salt	Domestic	-
17013-01-3	2-Butenedioic acid, (E)-, disodium salt	Cosmetic	-
17084-02-5	Iron, [N-[2-[bis(carboxymethyl)amino]ethyl]-N-(2-hydroxyethyl)glycinato(3-)]	Domestic	-
17099-81-9	Ferrate(1-), [[N,N'-1,2-ethanediylbis[N-(carboxymethyl)glycinato]](4-)-N,N',O,O',ON,ON']-, hydrogen, (OC-6-21)-	Domestic	-
17569-89-0	Ferrate(1-), [[N,N'-1,3-propanediylbis[N-(carboxymethyl)glycinato]](4-)-N,N',O,O',ON,ON']-, hydrogen, (OC-6-21)-	Commercial	-
18154-32-0	Ferrate(1-), [[N,N'-1,2-ethanediylbis[N-(carboxymethyl)glycinato]](4-)-N,N',O,O',ON,ON']-, sodium, trihydrate, (OC-6-21)-	Domestic	-
19529-38-5	Ferrate(2-), [N,N-bis[2-[bis(carboxymethyl)amino]ethyl]glycinato(5-)]-, disodium, (PB-7-13-12564)-	Domestic	-
20438-93-1	Ferrate(2-), [N,N-bis[2-[bis(carboxymethyl)amino]ethyl]glycinato(5-)]-, dihydrogen, (PB-7-13-12564)-	Commercial	-
21265-50-9	Ferrate(1-), [[N,N'-1,2-ethanediylbis[N-(carboxymethyl)glycinato]](4-)-N,N',O,O',ON,ON']-, ammonium, (OC-6-21)-	Domestic	-
21393-59-9	Ferrate(2-), [[N,N'-1,2-ethanediylbis[N-(carboxymethyl)glycinato]](4-)-N,N',O,O',ON,ON']-, dihydrogen, (OC-6-21)-	Commercial	-

CAS No	Chemical Name	Highest Use Category (Human Health)	Additional information
21626-24-4	Ferrate(1-), aqua[[N,N'-1,2-ethanediylbis[N-(carboxymethyl)glycinato]](4-)-N,N',O,O',ON,ON']-, sodium, (PB-7-11'-121'3'3)-	Commercial	-
39377-66-7	Magnesate(2-), [[N,N'-1,2-ethanediylbis[N-(carboxymethyl)glycinato]](4-)-N,N',O,O',ON,ON']-, magnesium(2+) (1:1), (OC-6-21)-	Domestic	-
54453-03-1	Cuprate(2-), [[N,N'-1,2-ethanediylbis[N-(carboxymethyl)glycinato]](4-)-N,N',O,O',ON,ON']-, dihydrogen, (OC-6-21)-	Domestic	-
54959-35-2	Ferrate(1-), [[N,N'-1,2-ethanediylbis[N-(carboxymethyl)glycinato]](4-)-N,N',O,O',ON,ON']-, potassium, (OC-6-21)-	Domestic	-
61788-72-5	Fatty acids, tall oil, epoxidized, octyl esters	Commercial	-
61789-01-3	Fatty acids, tall oil, epoxidized, 2-ethylhexyl esters	Commercial	-
68413-60-5	Ferrate(2-), [[N,N'-1,2-ethanediylbis[N-(carboxymethyl)glycinato]](4-)-N,N',O,O',ON,ON']hydroxy-, diammonium	Domestic	-
70024-68-9	Benzenesulfonic acid, mono-C16-24-alkyl derivatives, barium salts, overbased	Commercial	-
71302-79-9	Fatty acids, linseed-oil, epoxidized, 2-ethylhexyl esters	Commercial	-
73533-36-5	Ferrate(1-), [[N,N'-(1-methyl-1,2-ethanediyl)bis[N-(carboxymethyl)glycinato]](4-)-N,N',O,O',ON,ON']-, sodium, (OC-6-42)-	Domestic	-
73690-83-2	Ferrate(1-), [[N,N'-(1-methyl-1,2-ethanediyl)bis[N-(carboxymethyl)glycinato]](4-)-N,N',O,O',ON,ON']-, (OC-6-42)-	Commercial	-
85959-68-8	Ferrate(2-), [N,N-bis[2-[bis(carboxymethyl)amino]ethyl]glycinato(5-)]-, diammonium, (PB-7-13-12564)-	Domestic	-
91722-14-4	Soybean oil, epoxidized, acrylate	Commercial	-



CAS No	Chemical Name	Highest Use Category (Human Health)	Additional information
93028-28-5	Benzenesulfonic acid, C10-60-alkyl derivatives, barium salts	Commercial	-
100208-96-6	Iron, N,N-bis[2-[bis(carboxymethyl)amino]ethyl]glycine, sodium complexes	Domestic	-
103690-85-3	Ferrate(1-), [[N,N'-(1-methyl-1,2-ethanediyl)bis[N-(carboxymethyl)glycinato]](4-)-N,N',O,O',ON,ON']-, ammonium, (OC-6-42)-	Commercial	-
111030-91-2	Iron, N,N-bis[2-[bis(carboxymethyl)amino]ethyl]glycine, ammonium complexes	Commercial	-
111030-92-3	Iron, EDTA ammonium complexes	Domestic	-
111687-36-6	Ferrate(1-), [[N,N'-1,3-propanediylbis[N-(carboxymethyl)glycinato]](4-)-N,N',O,O',ON,ON']-, ammonium, (OC-6-21)-	Domestic	-
117198-20-6	Ferrate(1-), [[N,N'-1,3-propanediylbis[N-(carboxymethyl)glycinato]](4-)-N,N',O,O',ON,ON']-, (OC-6-21)-	Commercial	-
124268-99-1	Ferrate(1-), [[N,N'-1,3-propanediylbis[N-(carboxymethyl)glycinato]](4-)-N,N',O,O',ON,ON']-, potassium, (OC-6-21)-	Domestic	-
124269-00-7	Ferrate(1-), [[N,N'-1,3-propanediylbis[N-(carboxymethyl)glycinato]](4-)-N,N',O,O',ON,ON']-, sodium, (OC-6-21)-	Commercial	-
211450-54-3	Fatty acids, C16-18 and C18-unsatd., Me esters, epoxidized, reaction products with ethylene glycol	Commercial	-

## References

AICIS (Australian Industrial Chemicals Introduction Scheme) (2019), [\*The Industrial Chemicals Act 2019\*](#), AICIS, accessed 16 March 2023.

AICIS (Australian Industrial Chemicals Introduction Scheme) (n.d.), [\*The Australian Inventory of Industrial Chemicals \(Inventory\)\*](#), AICIS, accessed 16 March 2023.

